Search research articles
Contact Us
Filters
Showing results (71-80 of 101) with videos related to
Page
of 11
Sort By:
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
January 4, 2013
Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort
Nicholas E Power, Wassim Kassouf, David Bell, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
June 23, 2020
Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC
Geoffrey Gotto, Darrel E Drachenberg, Joseph Chin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 28, 2020
Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada
Mark T Corkum, Gerard Morton, Alexander V Louie, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
November 16, 2018
Characterization of clinical human prostate cancer lesions using 3.0-T sodium MRI registered to Gleason-graded whole-mount histopathology
Nolan C Broeke, Justin Peterson, Joseph Lee, et al.
Nature Communications
|
December 10, 2020
Author Correction: Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients
Brendan A Daisley, Ryan M Chanyi, Kamilah Abdur-Rashid, et al.
Nature Communications
|
September 25, 2020
Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients
Brendan A Daisley, Ryan M Chanyi, Kamilah Abdur-Rashid, et al.
European Urology Oncology
|
October 14, 2023
Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE)
Laurence Klotz, Joseph Chin, Peter C Black, et al.
Physics and Imaging in Radiation Oncology
|
September 30, 2021
Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation
Christopher W Smith, Ryan Alfano, Douglas Hoover, et al.
BMC Cancer
|
April 20, 2023
The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER)
Lucas C Mendez, Aneesh Dhar, David Laidley, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
January 4, 2013
Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada
Michael Metcalfe, Wassim Kassouf, Ricardo Rendon, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 101) with videos related to
Sort By:
Page
of 11
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
January 4, 2013
Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort
Nicholas E Power, Wassim Kassouf, David Bell, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
June 23, 2020
Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC
Geoffrey Gotto, Darrel E Drachenberg, Joseph Chin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 28, 2020
Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada
Mark T Corkum, Gerard Morton, Alexander V Louie, et al.
Journal of Magnetic Resonance Imaging : JMRI
|
November 16, 2018
Characterization of clinical human prostate cancer lesions using 3.0-T sodium MRI registered to Gleason-graded whole-mount histopathology
Nolan C Broeke, Justin Peterson, Joseph Lee, et al.
Nature Communications
|
December 10, 2020
Author Correction: Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients
Brendan A Daisley, Ryan M Chanyi, Kamilah Abdur-Rashid, et al.
Nature Communications
|
September 25, 2020
Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients
Brendan A Daisley, Ryan M Chanyi, Kamilah Abdur-Rashid, et al.
European Urology Oncology
|
October 14, 2023
Magnetic Resonance Imaging-Targeted Versus Systematic Prostate Biopsies: 2-year Follow-up of a Prospective Randomized Trial (PRECISE)
Laurence Klotz, Joseph Chin, Peter C Black, et al.
Physics and Imaging in Radiation Oncology
|
September 30, 2021
Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation
Christopher W Smith, Ryan Alfano, Douglas Hoover, et al.
BMC Cancer
|
April 20, 2023
The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER)
Lucas C Mendez, Aneesh Dhar, David Laidley, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
January 4, 2013
Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada
Michael Metcalfe, Wassim Kassouf, Ricardo Rendon, et al.
Page
of 11